This study aimed to evaluate gingival crevicular fluid (GCF) levels of fractalkine/CX3CL1 and CX3CR1 in patients with gingivitis and periodontitis before and after non-surgical periodontal therapy.

Thirty stage 3 periodontitis, thirty gingivitis and thirty periodontally healthy individuals were enrolled in the study. Clinical periodontal measurements were recorded; gingivitis and periodontitis patients underwent non-surgical periodontal treatment, and GCF samples were collected at baseline and at 1 and 3 months after treatment. CX3CL1 and CX3CR1 were determined by ELISA.

Inclusion Criteria:

1. 25-50 years of age
2. having at least 20 natural teeth, excluding third molars
3. having no systemic disease
4. non-smokers
5. criteria for healthy control group: BOP < 10% and PD ≤ 3 mm without clinical attachment loss or radiographic sign of alveolar bone destruction
6. criteria for stage 3 periodontitis group: interdental CAL ≥ 5 mm at least 2 non-adjacent teeth, PD ≥ 6 mm and radiographic bone loss extending to the mid-third of the root or beyond.

Exclusion Criteria:

1. having any systemic diseases,
2. smoking
3. current pregnancy or lactation
4. a history of periodontal treatment in the past 6 months
5. using antibiotic, anti-inflammatory drugs or any other drugs within the past 6 months.